HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

AbstractBACKGROUND:
A single preoperative high dose of methylprednisolone (15 to 30 mg/kg) has been advocated in surgery, because it may inhibit the surgical stress response and thereby improve postoperative outcome and convalescence. However, these potential clinical benefits must be weighed against possible adverse effects.
OBJECTIVE:
To conduct a risk-benefit analysis using a meta-analysis, to compare complication rates and clinical advantages associated with the use of high dose methylprednisolone in surgical patients.
METHODS:
Randomised controlled trials of high dose methylprednisolone in elective and trauma surgery were systematically searched for in various literature databases. Outcome data on adverse effects, postoperative pain and hospital stay were extracted and statistically pooled in fixed-effects meta-analyses.
RESULTS:
We located 51 studies in elective cardiac and noncardiac surgery, as well as traumatology. Pooled data failed to show any significant increase in complication rates. In patients treated with corticosteroids, nonsignificantly more gastrointestinal bleeding and wound complications were observed; the 95% confidence interval boundaries of the numbers-needed-to-harm were 59 and 38, respectively. The only significant finding was a reduction of pulmonary complications (risk difference -3.5%; 95% confidence interval -1.0 to -6.1), mainly in trauma patients.
CONCLUSION:
For patients undergoing surgical procedures, a perioperative single-shot administration of high dose methylprednisolone is not associated with a significant increase in the incidence of adverse effects. In patients with multiple fractures, limited evidence suggests promising benefits of glucocorticoids on pulmonary complications.
AuthorsS Sauerland, M Nagelschmidt, P Mallmann, E A Neugebauer
JournalDrug safety (Drug Saf) Vol. 23 Issue 5 Pg. 449-61 (Nov 2000) ISSN: 0114-5916 [Print] New Zealand
PMID11085349 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
Chemical References
  • Anti-Inflammatory Agents
  • Methylprednisolone Hemisuccinate
Topics
  • Animals
  • Anti-Inflammatory Agents (administration & dosage, adverse effects)
  • Humans
  • Methylprednisolone Hemisuccinate (administration & dosage, adverse effects)
  • Premedication
  • Preoperative Care
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: